PIK3CA and colorectal carcinoma: However, biomarkers associated with the PI3K/AKT/mTOR pathway, such as PIK3CA and PTEN, are not recommended for use in clinical practice due to insufficient evidence, especially associated with CRC treatment [34, 35].